A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis

International Journal of Nephrology and Renovascular Disease

Volumn 7, Issue , 2014, Pages 141-152

  Moustafa, Moustafa ^a   Lehrner, Lawrence ^b   Al Saghir, Fahd ^c   Smith, Mark ^d   Goyal, Sunita ^e   Dillon, Maureen ^e   Hunter, John ^e   Holmes Farley, Randy ^e  

^a South Carolina Nephrology and Hypertension Center   (United States)

^b Southern Nevada Pain Specialists   (United States)

^c Michigan Kidney Consultants   (United States)

^d Kidney Care Associates   (United States)

^e GENZYME CORPORATION   (United States)

Author keywords

Clinical trial; Hemodialysis; Serum phosphorus; Sevelamer carbonate

Indexed keywords

CALCIUM PHOSPHATE; CHOLESTEROL; GENZ 644470; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER CARBONATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NUTRITIONAL DISORDER; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SUBCUTANEOUS DISORDER; SUBCUTANEOUS TISSUE DISORDER; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

EID: 84898735673     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S56217     Document Type: Article

References (15)

1. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68(6):386-391.
2. Fan S, Ross C, Mitra S, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant. 2009;24(12):3794-3799.
3. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4): 1125-1130.
4. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179-1187.
5. Tomasello S, Dhupar S, Sherman RA. Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dial Transplant. 2004;33(5):236-242.
6. Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats. Nephrol Dial Transplant. 1997;12(5):961-964.
7. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium-and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12(8):1640-1644.
8. Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium-and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant. 1998;13(9):2303-2310.
9. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009;72(4):252-258.
10. Finn WF, Joy MS, Hladik GA; Lanthanum Study Group. Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. J Am Soc Nephrol. 1999;10:261A.
11. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29(1):66-71.
12. Fishbane S, Delmez J, Suki WN, et al. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis. 2010;55(2):307-315.
13. Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant. 2004;19(1):i19-i24.
14. Finn WF, Joy MS, Hladik G; Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004;62(3):193-201.
15. Chen N, Wu X, Ding X, et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrol Dial Transplant. 2014;29(1):152-160.